부광약품

003000KOSPI의약품 제조업

49.8 / 100

Reference Date: 2026-06-10

Financial Score19.0 / 40

News Sentiment18.8 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 29.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Bupyeong Pharmaceutical, established in 1960, is a pharmaceutical manufacturer and distributor specializing in products like Faloba and Dexid. In 2023, it achieved a profit turnaround with consolidated sales of 160.1 billion won and operating profit of 1.6 billion won, marking a 27% sales growth year-on-year.

Number of Employees

650people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

27.80Industry Average 11.930.0Point

2.3x industry avg (risky)

PBR

1.22Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

4.25Industry Average 4.014.0Point

In line with industry avg

Debt Ratio

5.15Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲26.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲439.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.6% (improving, 3yr)

Detailed News Sentiment

14 totalPositive 11Neutral 3Negative 0Average Sentiment Score 75.4

Positive
유니온제약 품은 부광약품…이사진 교체 추진
부광약품의 경영 정상화를 위한 인사 교체로 인해 긍정적인 시장 반응 예상.
Positive
기술수출 넘어 사업화로…K-바이오, 하반기 성과 입증 나선다
부광약품을 포함한 국내 바이오 기업들의 후속 개발 및 임상 확대 계획 발표로 하반기 성과 기대감 증가.
Positive
부광약품, ‘루라시돈’ 우울장애 치료 적응증 추가 IND 승인
부광약품의 루라시돈이 주요 우울장애 치료 적응증 확대 승인으로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 4,225Won52-week high 9,60052-week low 3,225

1-month return0.0Point

1m -29.58% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-05-29
Neutral분기보고서 (2026.03)2026-05-14
Neutral[기재정정]타법인주식및출자증권취득결정2026-05-13